Study details
Enrolling now
Vancomycin Study for Multiple Sclerosis (MS)
Icahn School of Medicine at Mount Sinai
NCT IDNCT05539729ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
12
Study length
about 3.7 years
Ages
18–50
Locations
1 site in NY
What this study is about
This trial is testing whether vancomycin affects the gut microbiome and immune function in people with multiple sclerosis. The goal is to understand how vancomycin might influence the connection between the gut and brain in MS.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Placebo
- 2.Take Vancomycin
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Injection / IV
How treatment is administered
Treatment Assignment
Randomized & Blinded
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
vancomycin
Drug routes
infusion
Body systems
Neurology